Lycera Corp. — a biotech spinoff from the University of Michigan that has been one of the state’s most successful fundraisers over the past decade — said today that it has entered into an agreement with Merck & Co. Inc. that could pay Lycera more than $300 million to develop and commercialize drugs that target key sources of inflammation in the body.
UM biotech spinoff Lycera could earn $300 million-plus from development deal with Merck
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.